关注结核病共患病已成为公共卫生的需要

doi:10.19983/j.issn.2096-8493.20220107

摘要/Abstract

中图分类号:

卢水华. 关注结核病共患病已成为公共卫生的需要[J]. 结核与肺部疾病杂志, 2022, 3(4): 255-260. doi: 10.19983/j.issn.2096-8493.20220107

参考文献 35

[1]	Bates M, O’Grady J, Maeurer M, et al. Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis, 2013, 13(1):36-42. doi: 10.1016/S1473-3099(12)70245-1. doi: 10.1016/S1473-3099(12)70245-1 URL
[2]	Swindells S, Ramchandawi R, Gupta A, et al. One Moth of Rifapentine plus Isoniazid to prevent HIV-Related Tuberculosis. N Engl J Med, 2019, 380(11): 1001-1011. doi: 10.1056/NEJMoa1806808. doi: 10.1056/NEJMoa1806808 URL
[3]	Nemes E, Geldenhuys H, Rozot V, et al. tuberculosis Infection with H4:IC 31 Vaccine or BCG Revaccination. N Engl J Med, 2018, 379(2):138-149. doi: 10.1056/NEJMoa1714021. doi: 10.1056/NEJMoa1714021 URL
[4]	Ottenhoff THM. A Trial of M72/AS01E Vaccine to Prevent Tuberculosis. N Engl J Med, 2020, 382(16):1576-1577. doi: 10.1056/NEJMc2001364. doi: 10.1056/NEJMc2001364 URL
[5]	Schrager LK, Vekemens J, Drager N, et al. The status of tuberculosis vaccine development. Lancet Infect Dis, 2020, 20(3)e28-e37.doi: 10.1016/S1473-3099(19)30625-5. doi: 10.1016/S1473-3099(19)30625-5
[6]	Zhu B, Dockrell HM, Ottenhoff THM, et al. Tuberculosis vaccines: Opportunities and challenges. Respirology, 2018, 23(4):359-368. doi: 10.1111/resp.13245. doi: 10.1111/resp.13245 URL
[7]	World Health Organization. Global tuberculosis report 2019. Geneva:World Health Organization,2019.
[8]	Elhadi M, Khaled A, Msherghi A. Infectious diseases as a cause of death among cancer patients: a trend analysis and population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results database. Infect Agent Cancer, 2021, 16(1):72. doi: 10.1186/s13027-021-00413-z. doi: 10.1186/s13027-021-00413-z URL
[9]	Lin CH, Lin CJ, Kuo YW, et al. Tuberculosis mortality: patient characteristics and causes. BMC Infect Dis, 2014, 14:5. doi: 10.1186/1471-2334-14-5. doi: 10.1186/1471-2334-14-5 URL
[10]	Puchner KP, Rodriguez-Fernandez R, Oliver M, et al. Non-communicable diseases and tuberculosis: Anticipating the impending global storm. Glob Public Health, 2019, 14(9):1372-1381. doi: 10.1080/17441692.2019.1580760. doi: 10.1080/17441692.2019.1580760 URL
[11]	Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with tuberculosis. Lancet Glob Health, 2019, 7(4):e448-e460. doi: 10.1016/S2214-109X(18)30487-X. doi: 10.1016/S2214-109X(18)30487-X
[12]	Shu CC, Liao KM, Chen YC, et al. The burdens of tuberculosis on patients with malignancy: incidence, mortality and relapse. Sci Rep, 2019, 9(1):11901. doi: 10.1038/s41598-019-48395-8. doi: 10.1038/s41598-019-48395-8 URL
[13]	Dong YH, Chang CH, Wu FL, et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: A systematic review and meta-analysis of randomized controlled trials. a systematic review and meta-analysis of randomized controlled trials. Chest, 2014, 145(6):1286-1297. doi: 10.1378/chest.13-2137. doi: 10.1378/chest.13-2137 URL
[14]	Hu HY, Wu CY, Huang N, et al. Increased risk of tuberculosis in patients with end-stage renal disease: a population-based cohort study in Taiwan, a country of high incidence of end-stage renal disease. Epidemiol Infect, 2014, 142(1):191-199. doi: 10.1017/S0950268813000551. doi: 10.1017/S0950268813000551 pmid: 23510593
[15]	Torre-Cisneros J, Doblas A, Aguado JM, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis, 2009, 48(12):1657-1665. doi: 10.1086/599035. doi: 10.1086/599035 pmid: 19445585
[16]	Lee HJ, Lee DG, Choi SM, et al. The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: High incidence compared with general population. PLoS One, 2017, 12(3):e0173250. doi: 10.1371/journal.pone.0173250. doi: 10.1371/journal.pone.0173250
[17]	Kedia S, Mouli VP, Kamat N, et al. Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis. Am J Gastroenterol, 2020, 115(3):340-349. doi: 10.14309/ajg.0000000000000527. doi: 10.14309/ajg.0000000000000527 URL
[18]	Sartori NS, de Andrade NPB, da Silva Chakr RM. Incidence of tuberculosis in patients receiving anti-TNF therapy for rheumatic diseases: a systematic review. Clin Rheumatol, 2020, 39(5):1439-1447. doi: 10.1007/s10067-019-04866-x. doi: 10.1007/s10067-019-04866-x URL
[19]	Hosseini M, Shakerimoghaddam A, Ghazalibina M, et al. Aspergillus coinfection among patients with pulmonary tuberculosis in Asia and Africa countries; A systematic review and meta-analysis of cross-sectional studies. Microb Pathog, 2020, 141:104018. doi: 10.1016/j.micpath.2020.104018. doi: 10.1016/j.micpath.2020.104018 URL
[20]	Wong RJ, Hubbard A, Bagley L, et al. Estimating Prevalence of Hepatitis B Virus Coinfection Among Adults With Tuberculosis: A Systematic Review With Meta-analysis. J Clin Gastroenterol, 2022, 56(7):601-617. doi: 10.1097/MCG.0000000000001533. doi: 10.1097/MCG.0000000000001533 URL
[21]	Behzadifar M, Heydarvand S, Behzadifar M, et al. Prevalence of Hepatitis C Virus in Tuberculosis Patients: A Systematic Review and Meta-Analysis. Ethiop J Health Sci, 2019, 29(1):945-956. doi: 10.4314/ejhs.v29i1.17. doi: 10.4314/ejhs.v29i1.17 pmid: 30700963
[22]	姚琳, 顾斌斌, 王霞芳, 等. 苏州地区2011年—2017年间9528例肺结核患者合并症的原因分析及其分布趋势. 抗感染药学, 2019, 16(2):258-261. doi: 10.13493/j.issn.1672-7878.2019.02-025. doi: 10.13493/j.issn.1672-7878.2019.02-025
[23]	邓岚兰, 杨新婷, 贾俊楠, 等. 2012—2016年北京市胸科医院肺结核合并症患者的回顾性分析. 疾病监测, 2018, 33(4):320-323.
[24]	Puchner KP, Rodriguez-Fernandez R, Oliver M, et al. Non-communicable diseases and tuberculosis: Anticipating the impending global storm. Glob Public Health, 2019, 14(9):1372-1381. doi: 10.1080/17441692.2019.1580760. doi: 10.1080/17441692.2019.1580760 URL
[25]	World Health Organization.World Health Statistics 2019.Geneva:World Health Organization, 2019.
[26]	The World Bank New World Bank country classifications by income level:2020-2021:[EB/OL].[2022-06-11]. https://blogs.worldbank.org/opendata/new-world-bank-country-classifications-income-level-2020-2021.
[27]	Sbrana E, Grise J, Stout C, et al. Co-morbidities associated with tuberculosis in an autopsy case series. Tuberculosis (Edinb), 2011, 91 Suppl 1:S38-42. doi: 10.1016/j.tube.2011.10.008. doi: 10.1016/j.tube.2011.10.008
[28]	Drug Interactions Checker[DB/OL].[2022-06-12]. https://www.drugs.com/drug_interactions.html.
[29]	Tao NN, Li YF, Song WM, et al. Risk factors for drug-resis-tant tuberculosis, the association between comorbidity status and drug-resistant patterns: a retrospective study of previously treated pulmonary tuberculosis in Shandong, China,during 2004—2019. BMJ Open, 2021, 11(6):e044349. doi: 10.1136/bmjopen-2020-044349. doi: 10.1136/bmjopen-2020-044349
[30]	何燕超, 揭志军. 综合医院活动性肺结核的早期筛查的进展与策略. 结核与肺部疾病杂志, 2022, 4(4):334-337. doi: 10.19983/j.issn.2096-8493.20220078. doi: 10.19983/j.issn.2096-8493.20220078
[31]	周伊南, 朱惠莉. 慢性阻塞性肺疾病合并肺结核的研究进展. 结核与肺部疾病杂志, 2022, 4(4):338-342. doi: 10.19983/j.issn.2096-8493.20220013. doi: 10.19983/j.issn.2096-8493.20220013
[32]	钱晓文, 翟晓文. 造血干细胞移植与结核病. 结核与肺部疾病杂志, 2022, 4(4):315-319. doi: 10.19983/j.issn.2096-8493.20220092. doi: 10.19983/j.issn.2096-8493.20220092
[33]	张晓林, 李锋. 肺结核致呼吸衰竭研究进展. 结核与肺部疾病杂志, 2022, 4(4):320-324. doi: 10.19983/j.issn.2096-8493.20220014. doi: 10.19983/j.issn.2096-8493.20220014
[34]	郦源, 郭茹茹, 吕良敬. 结缔组织病合并结核病的研究进展. 结核与肺部疾病杂志, 2022, 4(4):309-314. doi: 10.19983/j.issn.2096-8493.20220011. doi: 10.19983/j.issn.2096-8493.20220011
[35]	刘玉坤, 郭智. 慢性髓系白血病与结核病. 结核与肺部疾病杂志, 2022, 4(4):325-327. doi: 10.19983/j.issn.2096-8493.20220108. doi: 10.19983/j.issn.2096-8493.20220108

关注结核病共患病已成为公共卫生的需要

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 35

相关文章 15

编辑推荐

Metrics

本文评价

友情链接

[1]	陈禹, 李晓睿, 王妙然, 张雨颀, 刘畅, 王照华, 石杰, 樊丽超, 尹智华, 谢建平. 金属离子在结核病中的作用研究进展[J]. 结核与肺部疾病杂志, 2025, 6(1): 102-112.
[2]	徐雁南, 方梓昊, 赵文丽, 郑佳雄, 刘苏洋, 林健雄, 纪丽微, 常巧呈. 中国异烟肼耐药结核分枝杆菌基因突变特征分析[J]. 结核与肺部疾病杂志, 2025, 6(1): 14-21.
[3]	万莹, 庞学文, 张帆. 2010—2020年天津市结核病防治健康促进工作效果评价[J]. 结核与肺部疾病杂志, 2025, 6(1): 22-29.
[4]	赵永年, 张丽杰, 王童敏. 2014—2023年新疆生产建设兵团肺结核报告发病流行病学特征分析[J]. 结核与肺部疾病杂志, 2025, 6(1): 30-34.
[5]	郑建莉, 吴语媚, 张仕利, 杜恣闲, 李土荣, 陈石生, 林文革. 福建省龙岩市结核病重点高危人群主动筛查成本效果分析[J]. 结核与肺部疾病杂志, 2025, 6(1): 35-39.
[6]	杨艳, 董文, 陈建军, 张玉. 2014—2023年湖北省十堰市竹溪县肺结核流行特征分析[J]. 结核与肺部疾病杂志, 2025, 6(1): 40-45.
[7]	齐威, 赵恩奕. 2006—2020年天津市中心城区老年与非老年肺结核流行特征及变化趋势[J]. 结核与肺部疾病杂志, 2025, 6(1): 46-54.
[8]	阎庆虎, 薛峰, 于泳, 秦毅, 阎庆梅, 崔嘉. 超声引导下微波消融技术在局限性结核病变治疗中的价值分析[J]. 结核与肺部疾病杂志, 2025, 6(1): 55-60.
[9]	陈静, 秦娅莉, 王明栋, 杨儒斌, 王倩, 彭燕清, 邱继瑶, 张晓, 周昕艾. QuantiFERON-TB Gold Plus检测活动性肺结核的效能分析[J]. 结核与肺部疾病杂志, 2025, 6(1): 61-67.
[10]	顾金花, 张盼盼. 三种结核分枝杆菌检测方法在某综合医院的应用价值评估[J]. 结核与肺部疾病杂志, 2025, 6(1): 68-72.
[11]	闫文华, 陈文君. 数智化健康教育在菌阳肺结核患者陪护者预防管理中的价值[J]. 结核与肺部疾病杂志, 2025, 6(1): 73-78.
[12]	廖影, 庞艳, 赵静, 何高琴, 游茂林, 王蕾. 2018—2023年重庆市梁平区肺结核患者报告情况及发现延迟特征分析[J]. 结核与肺部疾病杂志, 2025, 6(1): 8-13.
[13]	张莹, 郭春辉. 结核性气管支气管狭窄的治疗研究进展[J]. 结核与肺部疾病杂志, 2025, 6(1): 87-93.
[14]	杨舒琪, 李锋. 程序性死亡受体1/程序性死亡-配体1抑制剂在结核病研究中的进展[J]. 结核与肺部疾病杂志, 2025, 6(1): 94-101.
[15]	欧庆芬. 非结核分枝杆菌肺病的CT诊断及鉴别诊断[J]. 结核与肺部疾病杂志, 2024, 5(S): 13-14.